Fortress Biotech, Inc.
FBIO
$3.83
$0.23996.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -10.21% | -13.50% | -12.80% | 1.78% | 1.59% |
| Total Other Revenue | -87.52% | -94.86% | -94.88% | 3,268.79% | 5,008.75% |
| Total Revenue | -28.23% | -32.11% | -31.76% | 31.51% | 31.68% |
| Cost of Revenue | -47.26% | -52.54% | -40.96% | -48.36% | -44.32% |
| Gross Profit | 209.10% | 113.05% | 58.45% | 101.29% | 90.57% |
| SG&A Expenses | 42.65% | 13.94% | -4.45% | -22.69% | -28.95% |
| Depreciation & Amortization | 2.93% | 15.76% | 34.11% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.75% | -26.37% | -27.20% | -36.22% | -36.28% |
| Operating Income | -8.76% | 22.07% | 24.37% | 57.94% | 56.47% |
| Income Before Tax | 16.90% | 22.83% | 21.60% | 32.38% | 52.32% |
| Income Tax Expenses | -22.12% | -22.12% | -22.12% | -24.07% | 15.81% |
| Earnings from Continuing Operations | 16.92% | 22.83% | 21.60% | 32.36% | 52.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 11.60% | -21.74% | -19.95% | -28.08% | -48.24% |
| Net Income | 63.80% | 24.49% | 24.14% | 38.05% | 57.51% |
| EBIT | -8.76% | 22.07% | 24.37% | 57.94% | 56.47% |
| EBITDA | -9.62% | 22.40% | 24.32% | 58.82% | 57.21% |
| EPS Basic | 70.25% | 64.92% | 68.11% | 72.11% | 76.53% |
| Normalized Basic EPS | 146.51% | 159.62% | 146.44% | 151.26% | 68.86% |
| EPS Diluted | 69.02% | 64.89% | 68.09% | 72.10% | 76.52% |
| Normalized Diluted EPS | 143.66% | 159.62% | 146.44% | 151.26% | 68.86% |
| Average Basic Shares Outstanding | 84.37% | 111.50% | 150.40% | 137.88% | 105.24% |
| Average Diluted Shares Outstanding | 89.85% | 111.50% | 150.40% | 137.88% | 105.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.00% | 0.67% | 0.34% | -0.21% | -1.35% |